[89]
Janssen argues that the prior art cited by Novopharm in its NOA with respect to lack of novelty, does not anticipate the discovered advantages of the particular optical isomer disclosed in the '080 patent. Counsel refers to
May, Re
(1978), 197 U.S.P.Q. 601 (C.C.P.A.), a U.S. Court of Customs and Patent Appeals decision in which a patent claim to a (-) compound was found not lacking in novelty even though the prior art disclosed its racemate.